Baird raises target for Cencora stock to USD 373.00

Published on 10/14/2026 at 13:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal third-quarter revenue reached USD 84.80 billion, up 5.10 percent year over year. Cencora stock costs EUR 296.00 on October 14, 2026.

Target revision and November results

Robert W. Baird lifted its Cencora target from USD 370.00 to USD 373.00 on October 12, 2026.
Fiscal third-quarter revenue reached USD 84.80 billion, up 5.10 percent year over year.
Cencora stock was trading at EUR 296.00 at 1:49 p.m. CEST at Lang & Schwarz on October 14, 2026.
Cencora plans to publish fiscal fourth-quarter results on November 4, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Robert W. Baird lifted its price objective for Cencora stock from USD 370.00 to USD 373.00 and kept an Outperform rating in a report dated October 12, 2026, as reported by Ground News. The target revision gives the stock a fresh valuation reference while the next company report is already scheduled.

Third-quarter figures set the baseline

In the fiscal third quarter ended June 30, 2026, Cencora generated USD 84.80 billion in revenue, an increase of 5.10 percent from the prior-year quarter. Adjusted operating income rose 17.00 percent, while adjusted earnings per share increased 12.00 percent, according to the company's fiscal third-quarter earnings call carried by Yahoo Finance on August 5, 2026.

Three dates explain the setup

On August 5, 2026, Cencora reported fiscal third-quarter revenue of USD 84.80 billion. On October 2, 2026, the company announced a November 4, 2026 release date for fiscal fourth-quarter results. On October 12, 2026, Baird raised its price objective from USD 370.00 to USD 373.00, providing the most recent dated valuation signal.

What does the higher target mean?

The operating picture combines 5.10 percent revenue growth with 17.00 percent adjusted operating-income growth in fiscal third-quarter 2026. Management also raised adjusted fiscal 2026 earnings-per-share guidance to USD 17.75-17.95 from USD 17.70-17.90, according to Yahoo Finance. The next report will test whether that guidance range remains supported by demand across Cencora's US and international healthcare solutions businesses.

Price and valuation before results

Cencora was trading at EUR 296.00 at Lang & Schwarz on October 14, 2026 at 1:49 p.m. CEST. The primary listing is on the NYSE, where the latest structured quote showed USD 330.11 on October 13, 2026, with a 52-week range of USD 244.82 to USD 377.54 and a market capitalization of USD 64.2 billion. The next results are scheduled for November 4, 2026 before the NYSE open, with the conference call at 8:30 a.m. ET, according to Cencora. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.